Acadian Asset Management
LXEO icon

Acadian Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Acadian Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,909
Closed -$505K – 2157
2025
Q4 		$505K Buy
+50,909
New +$465K ﹤0.01% 1301
2025
Q2 		– Sell
-24,648
Closed -$85K – 1766
2025
Q1 		$85K Buy
+24,648
New +$109K ﹤0.01% 1373

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management's LXEO Position: Q1 2026 in Review

Acadian Asset Management sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 50,909 shares — an estimated $505K sold.

Acadian Asset Management first reported a position in LXEO in Q1 2025 and held it in 2 quarters. The position peaked at $505K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Acadian Asset Management reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 50,909 Lexeo Therapeutics shares in Q1 2026, an estimated $505K.
  • Acadian Asset Management first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 2 quarters.
  • Acadian Asset Management's Lexeo Therapeutics position peaked at $505K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.